NCT02996682View on ClinicalTrials.gov

Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis

PHASE3CompletedINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

December 26, 2016

Primary Completion Date

February 13, 2018

Study Completion Date

May 8, 2018

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

SOF/VEL

400/100 mg FDC tablet administered orally once daily

DRUG

RBV

Capsules administered orally in a divided daily dose

Trial Locations (33)

Unknown

Shimonoseki

Bunkyō City

Chiba

Chūō

Ehime

Fukui

Fukuyama-shi

Hiroshima

Ibaraki

Ichikawa

Iizuka

Iruma

Izunokuni

Kashibara

Kofu

Kumamoto

Kurume

Kyoto

Miyazaki

Morioka

Musashino

Nagoya

Nishinomiya

Okayama

Osaka

Ōmura

Sapporo

Sendai

Shimotsuga-gun

Suita

Takamatsu

Ube

Yamagata

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY